TREATMENT OF EARLY AGE MANIA (TEAM)

早期躁狂症的治疗（团队）

• 批准号: 7604564
• 负责人: John T. Walkup
• 金额: $ 0.41万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604564
• 关键词: Adolescent; Adult; Age; Behavior; Child; Computer Retrieval of Information on Scientific Projects Database; Early treatment; Evaluation; Funding; Grant; Institution; Lithium; Lithonate; Manic; Medicine; Names; Pharmaceutical Preparations; Purpose; Research; Research Personnel; Resources; Risperidone; Source; Teenagers; Testing; United States Food and Drug Administration; United States National Institutes of Health; Valproic Acid; Week; follow-up; valproate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. PURPOSE OF THE STUDY The purpose of the TEAM study is to evaluate the usefulness of three different medicines for children and teenagers ages 6 to 15.11 with mania. Mania is a term used to describe an illness in which children may feel so good or irritable leading to behavior that impairs their functioning. The three study medications are lithium, valproate, and risperidone. DESCRIPTION OF THE STUDY There are 3 parts to the TEAM study. The first part of the TEAM study is a baseline assessment. The second part is the medication treatment evaluation (8-16 weeks long). The last part is a 6-month follow-up assessment. Therefore, this study will take up to 10 months to complete. The study medications are risperidone (trade name Risperdal), lithium (trade name Eskalith), and valproate (trade name Depakote). These study medications are approved for use in adults with mania, but they have not yet been tested or approved by the FDA for treatment of mania in children or adolescents. There will be approximately 110 subjects participating here at Johns Hopkins. There will be up to 540 subjects participating in this study across the U.S.A.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 研究目的 团队研究的目的是评估三种不同药物对躁狂症6至15.11岁的儿童和青少年的有用性。 躁狂症是一个用来描述一种疾病的术语，在这种疾病中，儿童可能会感到如此好或烦躁，从而导致行为损害其功能。 这三种研究药物是锂，丙戊酸和利培酮。 研究的描述 团队学习有3个部分。 团队研究的第一部分是基线评估。第二部分是药物治疗评估（长8-16周）。最后一部分是6个月的随访评估。因此，这项研究最多将需要10个月才能完成。研究药物是利培酮（Risperdal），锂（商品名Eskalith）和瓣膜（商品名Depakote）。 这些研究药物被批准用于躁狂症的成年人，但尚未经FDA对儿童或青少年的躁狂症进行测试或批准。 约翰·霍普金斯（Johns Hopkins）将大约有110名受试者参加。 整个美国的这项研究最多将有540名受试者参加。